Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
OSAKA, Japan, May 11, 2016 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended...
-
Disclaimer: The following document is a translation of a press release prepared in Japanese. The Japanese version is the original version and can be found on the company's website:...
-
OSAKA, Japan, May 12, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015)...
-
OSAKA, Japan, March 25, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European...
-
OSAKA, Japan, March 2, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA)...
-
OSAKA, Japan, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen") hereby announces that it was resolved at the Board of Director meeting held on September...
-
OSAKA, Japan, July 2, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, Japan) (Santen) announced the closing of an asset purchase agreement ("Agreement") which was entered on May 13,...
-
OSAKA, Japan, May 13, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd., (Osaka, Japan) (Santen) announced today that it has entered into an Agreement with Merck & Co., Inc., (Whitehouse...
-
OSAKA, Japan, April 26, 2013 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (the "Company") announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the...
-
OSAKA, Japan, June 25, 2012 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that Bausch + Lomb (Rochester, New York) received approval of enVista™, the first glistening-free,...